Company

Zura Bio Limited

Zura Bio develops medicines for severe immune and inflammatory disorders.

About

Founded in 2022, Zura Bio is a clinical-stage biotechnology company developing medicines for immune and inflammatory disorders. Its pipeline includes ZB-168, an IL7R a inhibitor, and torudokimab, a monoclonal antibody that neutralizes IL33. In April 2023, Deep Track Capital, Great Point Partners, and Suvretta Capital Management acquired 18.8 million shares for USD 80 million, or USD 4.25 apiece. The company has team members in the UK and the USA.

2Funding rounds

5Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in